To examined whether activated T cells play a role in the anti-tumor effects of CD276 cKO, we block T lymphocytes following MB49 subcutaneous implantation by injection of anti-CD4 or anti-CD8 antibodies (Supplementary Fig. 4m). This evidence concerns the gene CD8A and neoplasm.